ClinicalTrials.Veeva

Menu
S

Spokane Eye Clinical Research | Spokane, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Lampalizumab
APL-2
Pegcetacoplan
Aflibercept
JNJ-81201887
Galegenimab
Vamikibart
Razuprotafib
Bimatoprost

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 42 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula,...

Enrolling
Age-Related Macular Degeneration
Drug: Acyclovir
Drug: trimethoprim-sulfamethoxazole
Recently updated

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting
Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Ranibizumab
Drug: Zifibancimig

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: Aflibercept
Drug: CLS-AX

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

Trial sponsors

Roche logo
Genentech logo
Jaeb Center for Health Research logo
A
Allergan logo
A
Bayer logo
AbbVie logo
Astellas logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems